SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : DBOT - Demegen, Inc.
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: jmhollen who started this subject11/10/2002 2:04:10 PM
From: jmhollen   of 4
 
Recent News:

11/5/02 Demegen Receives Orphan Drug Designation for P113D for Treatment of Cystic Fibrosis

9/12/02 Shareholder Meeting Remarks by Richard D. Ekstrom

8/27/02 Demegen Awarded European Patents for D-Amino Acid Peptides

1/29/02 Demegen Announces Organizational Changes -- Reduces Operating Costs and Will Focus on Co-Development and Licensing
-- Company Has Four Excellent Drug Candidates in Pipeline

1/8/02 Demegen Scientists Publish Antibacterial Activity of P113D against Cystic Fibrosis Infections

10/24/01 Demegen Receives Another Research Grant from the CFF to Expand Pipeline for the Treatment of Cystic Fibrosis Pulmonary Infections

8/22/01 Demegen Receives $1.5 Million Grant to Develop a Treatment for Cystic Fibrosis Infections

.
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2026 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News